Clinical Trial Update: A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure [Phase 2]

View source ↗

Summary

Phase II dose-escalation study evaluating Feasibility and Safety of transendocardial delivery of allogeneic MPCs in subjects with heart failure; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Mesoblast MPCs (mesenchymal precursor cells)

Snippet

Sponsor: Mesoblast, Ltd. | Conditions: Heart Failure | Phase 2 | Status: COMPLETED